| Cloning and characterization of microRNAs from rainbow trout (Oncorhynchus mykiss): Their expression during early embryonic development RK Ramachandra, M Salem, S Gahr, CE Rexroad, J Yao BMC developmental biology 8, 1-11, 2008 | 122 | 2008 |
| PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy PG Sasikumar, NS Sudarshan, S Adurthi, RK Ramachandra, DS Samiulla, ... Communications biology 4 (1), 699, 2021 | 89 | 2021 |
| Molecular characterization and expression profiles of cyclin B1, B2 and Cdc2 kinase during oogenesis and spermatogenesis in rainbow trout (Oncorhynchus mykiss) GF Qiu, RK Ramachandra, CE Rexroad III, J Yao Animal Reproduction Science 105 (3-4), 209-225, 2008 | 50 | 2008 |
| A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy PG Sasikumar, RK Ramachandra, S Adurthi, AA Dhudashiya, ... Molecular cancer therapeutics 18 (6), 1081-1091, 2019 | 45 | 2019 |
| ODM-203, a selective inhibitor of FGFR and VEGFR, shows strong antitumor activity, and induces antitumor immunity TH Holmström, AM Moilanen, T Ikonen, ML Björkman, T Linnanen, ... Molecular Cancer Therapeutics 18 (1), 28-38, 2019 | 23 | 2019 |
| Abstract B006: Functional antagonism of VSIG8-mediated immune suppression by oral VISTA agents PG Sasikumar, SS Naremaddepalli, RK Ramachandra, N Gowda, ... Molecular Cancer Therapeutics 17 (1_Supplement), B006-B006, 2018 | 21 | 2018 |
| Assessment of AFLP marker based genetic diversity in chilli (Capsicum annuum L. & C. baccatum L.) SL Krishnamurthy, Y Prashanth, AM Rao, KM Reddy, R Ramachandra NISCAIR-CSIR, India, 2015 | 20 | 2015 |
| Identification of OORP‐T, a novel oocyte‐specific gene encoding a protein with a conserved oxysterol binding protein domain in rainbow trout RK Ramachandra, SE Lankford, GM Weber, CE Rexroad III, J Yao Molecular Reproduction and Development: Incorporating Gamete Research 74 (4 …, 2007 | 18 | 2007 |
| A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events P Sasikumar, R Shrimali, S Adurthi, R Ramachandra, L Satyam, ... Journal for ImmunoTherapy of Cancer 1, 1-1, 2013 | 17 | 2013 |
| Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy P Sasikumar, NS Sudarshan, N Gowda, DS Samiulla, R Ramachandra, ... AACR annual meeting, 2016 | 15 | 2016 |
| Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway PG Sasikumar, LK Satyam, RK Shrimali, K Subbarao, R Ramachandra, ... Cancer Research 72 (8_Supplement), 2850-2850, 2012 | 15 | 2012 |
| Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of … AS Lazorchak, T Patterson, Y Ding, PG Sasikumar, NS Sudarshan, ... Cancer Immunology Research 5 (3_Supplement), A36-A36, 2017 | 12 | 2017 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| Debio 0617B inhibits growth of STAT3-driven solid tumors through combined inhibition of JAK, SRC, and class III/V receptor tyrosine kinases M Murone, A Vaslin Chessex, A Attinger, R Ramachandra, SJ Shetty, ... Molecular cancer therapeutics 15 (10), 2334-2343, 2016 | 11 | 2016 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| Conjoint therapies for immunomodulation PGN Sasikumar, M Ramachandra, RK Ramachandra, AS Lazorchak, ... US Patent 11,497,735, 2022 | 7 | 2022 |
| Pre-clinical efficacy in multiple syngeneic models with oral immune checkpoint antagonists targeting PD-L1 and TIM-3 P Sasikumar, N Sudarshan, R Ramachandra, N Gowda, D Samiulla, ... Eur J Cancer 1 (69), S98, 2016 | 4 | 2016 |
| Potent and selective inhibition of CDK7 by novel covalent inhibitors LK Satyam, R Poddutoori, S Mukherjee, S Marappan, S Gopinath, ... Cancer Research 76 (14_Supplement), 3070-3070, 2016 | 4 | 2016 |
| AUPM‐170: first‐in‐class, oral immune checkpoint inhibitor of PD‐L1/2 and VISTA P Sasikumar, N Sudarshan, N Gowda, DS Samiulla, RK Ramachandra, ... AACR annual meeting, 2015 | 4 | 2015 |
| Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway. PG Sasikumar, LK Satyam, R Shrimali, R Ramachandra, KA Reddy, ... Cancer Research 73 (8_Supplement), 1231-1231, 2013 | 3 | 2013 |
